Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
76%
Advanced Cancer
68%
Clinical Trial
66%
Diseases
64%
Malignant Neoplasm
52%
Adverse Event
47%
Pembrolizumab
44%
Overall Survival
33%
Progression Free Survival
30%
Bevacizumab
29%
Phase I Trials
29%
Antitumor Activity
27%
Pharmacokinetic
21%
Maximum Tolerated Dose
20%
Epidermal Growth Factor Receptor
19%
Selinexor
18%
Paclitaxel
16%
Mammalian Target of Rapamycin Inhibitor
15%
Diarrhea
15%
Programmed Death 1 Ligand 1
14%
Colorectal Carcinoma
14%
Thrombocytopenia
13%
Vasculotropin
13%
Tolerability
13%
Non Small Cell Lung Cancer
13%
Connective Tissue Cancer
13%
Breast Cancer
12%
Immunotherapy
12%
Cetuximab
12%
Neratinib
11%
Monotherapy
11%
Melanoma
11%
Carboplatin
11%
Rash
11%
Biological Marker
10%
Combination Therapy
10%
Chemotherapy
9%
Everolimus
9%
Uterine Cervix Cancer
9%
Erlotinib
9%
Ovary Cancer
9%
Pazopanib
9%
Temsirolimus
9%
Nausea
9%
Squamous Cell Carcinoma
8%
Pharmacodynamics
8%
Oxaliplatin
8%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Neutropenia
7%
Keyphrases
Advanced Solid Tumors
62%
Patients with Advanced Cancer
51%
Pembrolizumab
44%
Stable Disease
43%
Partial Response
39%
Phase I Study
36%
Phase I Clinical Trial
31%
Phase I Trial
28%
Tumor
26%
Bevacizumab
26%
Dose-limiting Toxicity
24%
Antitumor Activity
22%
MD Anderson Cancer Center
21%
Treatment-related Adverse Events
20%
Objective Response Rate
20%
Programmed Death-ligand 1 (PD-L1)
19%
Maximum Tolerated Dose
18%
Overall Survival
18%
Targeted Therapy
18%
Non-small Cell Lung Cancer (NSCLC)
17%
Confidence Interval
17%
Tumor Subtype
16%
Early Phase Clinical Trials
16%
Selinexor
16%
MTOR Inhibitor
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
15%
Adverse Events
14%
Metastatic Tumor
14%
Median Progression-free Survival
14%
Dose-escalation Study
14%
Advanced Malignancies
14%
Advanced Cancer
14%
Dose Level
14%
PIK3CA mutation
13%
Cetuximab
13%
Solid Tumors
13%
Dose Escalation
13%
Paclitaxel
12%
Progression-free Survival
12%
Advanced or Metastatic
12%
Diarrhea
12%
Median Overall Survival
12%
Sarcoma
12%
Everolimus
11%
Clinical Benefit
11%
Thrombocytopenia
11%
First-in-human
11%
PIK3CA
11%
Tolerability
11%
Medicine and Dentistry
Neoplasm
64%
Clinical Trial
53%
Advanced Cancer
47%
Malignant Neoplasm
40%
Cancer
39%
Pembrolizumab
37%
Diseases
31%
Overall Survival
28%
Solid Malignant Neoplasm
28%
Progression Free Survival
26%
Targeted Therapy
26%
Adverse Event
18%
Immunotherapy
15%
Antineoplastic Activity
14%
Breast Cancer
14%
Connective Tissue Cancer
14%
Next Generation Sequencing
12%
Mammalian Target of Rapamycin Inhibitor
11%
Arm
11%
Phase I Trials
11%
Non Small Cell Lung Cancer
10%
Programmed Death 1 Ligand 1
10%
Colorectal Carcinoma
10%
Metastatic Carcinoma
9%
Bevacizumab
9%
Oncology
9%
Biological Marker
9%
Squamous Cell Carcinoma
9%
Epidermal Growth Factor Receptor
8%
Phosphotransferase
8%
Cell-Free DNA
7%
Diarrhea
7%
Personalized Medicine
7%
Selinexor
7%
Systemic Therapy
7%
Hazard Ratio
7%
Vasculotropin
7%
Melanoma
6%
Thrombocytopenia
6%
PI3K/AKT/mTOR Pathway
6%
Ovarian Cancer
6%
Everolimus
6%
Experimental Therapy
6%
MEK Inhibitor
6%
Mammalian Target of Rapamycin
6%
Carcinoma
6%
Neratinib
6%
Cervical Cancer
6%
Cancer Therapy
6%
Vorinostat
5%